Sign in or create an account to add this stock to your watchlist.
About Seattle Genetics (NASDAQ:SGEN)
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.78
Quick Ratio3.35
Price-To-Earnings
Trailing P/E Ratio-64.51
Forward P/E Ratio-33.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$482.25 million
Price / Sales18.63
Cash FlowN/A
Price / CashN/A
Book Value$8.09 per share
Price / Book7.02
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-34.51%
Return on Equity-29.74%
Return on Assets-23.94%
Miscellaneous
Employees1,100
Outstanding Shares158,220,000
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics (NASDAQ:SGEN) issued its earnings results on Thursday, April, 26th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.31. The biotechnology company earned $140.59 million during the quarter, compared to the consensus estimate of $119.04 million. Seattle Genetics had a negative return on equity of 29.74% and a negative net margin of 34.51%. The company's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.42) earnings per share. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What price target have analysts set for SGEN?
17 analysts have issued twelve-month price targets for Seattle Genetics' shares. Their forecasts range from $48.00 to $75.00. On average, they anticipate Seattle Genetics' stock price to reach $63.7143 in the next twelve months. View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. Cann analysts commented, "We have not included any sales or earnings from enfortumab vedotin by 2022 due to its stage of development, but we are encouraged by its development program, including data in the ASCO abstract and its having received Breakthrough Therapy Designation. Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or 63.8% of total revenue, in 2017. We estimate that Adcetris sales, including additional indications, CTCL and Anaplastic large cell lymphoma, and label expansion into frontline Hodgkin’s lymphoma, will increase to $766.7 million in 2022 and account for 70% of revenue. Continued strong data from ECHELON-1 are expected to drive adoption in the frontline Hodgkin’s setting." (5/17/2018)
- 2. According to Zacks Investment Research, "Seattle Genetics' dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. However, efforts to expand Adcetris’s label is encouraging. The label expansion in pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. Meanwhile, the company’s shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of Q1 results. Seattle Genetics has a mixed record of earnings surprises in the recent quarters." (4/23/2018)
- 3. HC Wainwright analysts commented, "to Approval on June 25 PDUFA; Raise PT to $31 Stock Data 02/06/2018 Price $10.79 Exchange NASDAQ Price Target $31.00 52-Week High $27.79 52-Week Low $9.88 Enterprise Value (M) $282.5 Market Cap (M) $457 Public Market Float (M) 23.8 Shares Outstanding (M) 42.4 3 Month Avg Volume 1,154,580 Short Interest (M) 10.70 Shares Outstanding (M): Figure shown is as of November 2, 2017. Balance Sheet Metrics Cash (M) $199.4 Total Debt (M) $24.9 Total Cash/Share $4.70 Book Value/Share $3.55 Cash (M): Amount shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.66) (0.93)A (0.79) 2Q (0.87) (0.78)A (0.82) 3Q (0.41) (0.85)A (0.76) 4Q (1.04) (0.83) (0.75) FY (3.00) (3.10) (3.11) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 5.8 7.5A 0.6 2Q 9.1 1.3A 0.7 3Q 16.0 0.6A 1.2 4Q 10.7 0.8 1.8 FY 41.8 10.1 4.3 30 25 20 15 10 5 FEB- 17 J UN- 17 OCT- 17 FEB- 18 6 5 4 3 2 1 0 Vol. (mil) Price Manufacturing overhang lifted with VAI status at McPherson site." (2/7/2018)
- 4. JPMorgan Chase analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today. The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint. In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include Novozymes (NVZMY), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI) and Repligen (RGEN).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 57)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 57)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
- Dr. Jonathan G. Drachman, Chief Medical Officer and Exec. VP of R&D (Age 56)
Has Seattle Genetics been receiving favorable news coverage?
Media coverage about SGEN stock has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Seattle Genetics earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 48.71 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (32.10%), Baillie Gifford & Co. (9.27%), BlackRock Inc. (5.37%), Manning & Napier Group LLC (1.48%), Wasatch Advisors Inc. (0.62%) and Pinnacle Associates Ltd. (0.57%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which institutional investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Legal & General Group Plc, Manning & Napier Group LLC, Pinnacle Associates Ltd., Russell Investments Group Ltd., Swiss National Bank, Opus Point Partners Management LLC and Great West Life Assurance Co. Can. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which institutional investors are buying Seattle Genetics stock?
SGEN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Wells Fargo & Company MN, UBS Group AG, Bedell Frazier Investment Counseling LLC, JPMorgan Chase & Co., Millennium Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Seattle Genetics stock in the last two years include Bros Advisors Lp Baker and Felix Baker. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $56.77.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $8.98 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Seattle Genetics (NASDAQ:SGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
17 Wall Street analysts have issued ratings and price targets for Seattle Genetics in the last 12 months. Their average twelve-month price target is $63.7143, suggesting that the stock has a possible upside of 12.23%. The high price target for SGEN is $75.00 and the low price target for SGEN is $48.00. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.53 | 2.53 | 2.53 | 2.38 |
| Ratings Breakdown: | 0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $63.7143 | $63.7143 | $64.00 | $62.9333 |
| Price Target Upside: | 12.23% upside | 18.21% upside | 22.72% upside | 8.58% upside |
Seattle Genetics (NASDAQ:SGEN) Consensus Price Target History
Seattle Genetics (NASDAQ:SGEN) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Seattle Genetics (NASDAQ:SGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Seattle Genetics (NASDAQ SGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 33.80%
Institutional Ownership Percentage: 92.98%
Seattle Genetics (NASDAQ SGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2018 | Clay B. Siegall | CEO | Sell | 18,832 | $54.97 | $1,035,195.04 | |  |
| 5/9/2018 | Darren S. Cline | EVP | Sell | 9,000 | $55.33 | $497,970.00 | | |
| 5/8/2018 | Bros. Advisors Lp Baker | Director | Buy | 460,651 | $53.34 | $24,571,124.34 | | |
| 5/4/2018 | Bros. Advisors Lp Baker | Director | Buy | 204,537 | $52.68 | $10,775,009.16 | | |
| 5/3/2018 | Darren S. Cline | EVP | Sell | 4,000 | $53.81 | $215,240.00 | | |
| 5/1/2018 | Bros. Advisors Lp Baker | Director | Buy | 306,917 | $51.36 | $15,763,257.12 | | |
| 4/9/2018 | Clay B. Siegall | Insider | Sell | 18,832 | $50.52 | $951,392.64 | | |
| 3/15/2018 | Vaughn B. Himes | Insider | Sell | 5,000 | $58.12 | $290,600.00 | | |
| 3/9/2018 | Clay B. Siegall | CEO | Sell | 18,832 | $57.32 | $1,079,450.24 | | |
| 3/5/2018 | Jonathan G. Drachman | CMO | Sell | 10,457 | $52.83 | $552,443.31 | | |
| 2/9/2018 | Clay B. Siegall | Insider | Sell | 18,832 | $49.75 | $936,892.00 | | |
| 2/1/2018 | Bros. Advisors Lp Baker | Director | Buy | 3,846,153 | $52.00 | $199,999,956.00 | | |
| 1/11/2018 | Clay B. Siegall | Insider | Sell | 18,832 | $51.71 | $973,802.72 | | |
| 12/11/2017 | Clay B. Siegall | Insider | Sell | 18,832 | $55.40 | $1,043,292.80 | | |
| 12/4/2017 | Eric Dobmeier | COO | Sell | 3,729 | $58.75 | $219,078.75 | | |
| 11/30/2017 | Vaughn B. Himes | Insider | Sell | 10,000 | $59.97 | $599,700.00 | | |
| 11/17/2017 | Eric Dobmeier | COO | Sell | 35,000 | $58.25 | $2,038,750.00 | | |
| 11/15/2017 | Eric Dobmeier | COO | Sell | 9,600 | $57.80 | $554,880.00 | | |
| 11/15/2017 | Marc E. Lippman | Director | Sell | 3,000 | $58.07 | $174,210.00 | | |
| 11/10/2017 | Clay B. Siegall | Insider | Sell | 18,832 | $58.00 | $1,092,256.00 | | |
| 11/1/2017 | Todd E. Simpson | CFO | Sell | 39,385 | $60.91 | $2,398,940.35 | | |
| 10/11/2017 | Clay B Siegall | Insider | Sell | 18,832 | $61.18 | $1,152,141.76 | | |
| 9/11/2017 | Clay B. Siegall | Insider | Sell | 18,832 | $53.49 | $1,007,323.68 | | |
| 9/8/2017 | Vaughn B. Himes | Insider | Sell | 10,000 | $53.22 | $532,200.00 | | |
| 9/6/2017 | Darren S. Cline | EVP | Sell | 5,024 | $51.94 | $260,946.56 | | |
| 9/6/2017 | Todd E. Simpson | CFO | Sell | 9,638 | $52.00 | $501,176.00 | | |
| 8/31/2017 | Darren S. Cline | EVP | Sell | 7,569 | $52.51 | $397,448.19 | | |
| 8/31/2017 | Eric Dobmeier | COO | Sell | 25,000 | $52.24 | $1,306,000.00 | | |
| 8/28/2017 | Clay B. Siegall | CEO | Sell | 25,506 | $47.89 | $1,221,482.34 | | |
| 8/28/2017 | Darren S. Cline | EVP | Sell | 1,788 | $47.89 | $85,627.32 | | |
| 8/28/2017 | Eric Dobmeier | COO | Sell | 5,343 | $47.89 | $255,876.27 | | |
| 8/28/2017 | Jonathan G. Drachman | CMO | Sell | 8,502 | $47.89 | $407,160.78 | | |
| 8/28/2017 | Todd E. Simpson | CFO | Sell | 4,937 | $47.89 | $236,432.93 | | |
| 8/28/2017 | Vaughn B. Himes | Insider | Sell | 6,377 | $47.89 | $305,394.53 | | |
| 8/24/2017 | Jonathan G. Drachman | CMO | Sell | 10,000 | $47.54 | $475,400.00 | | |
| 8/7/2017 | Clay B. Siegall | Insider | Sell | 10,413 | $48.91 | $509,299.83 | | |
| 8/7/2017 | Darren S. Cline | EVP | Sell | 6,000 | $49.19 | $295,140.00 | | |
| 7/27/2017 | Jonathan G. Drachman | CMO | Sell | 10,000 | $54.54 | $545,400.00 | | |
| 7/5/2017 | Clay B. Siegall | CEO | Sell | 10,423 | $51.98 | $541,787.54 | | |
| 6/22/2017 | Jonathan G Drachman | CMO | Sell | 10,000 | $64.01 | $640,100.00 | 125,204 | |
| 6/5/2017 | Clay B. Siegall | Insider | Sell | 10,423 | $65.21 | $679,683.83 | | |
| 4/5/2017 | Clay B Siegall | Insider | Sell | 14,465 | $62.99 | $911,150.35 | 646,858 | |
| 3/31/2017 | Vaughn B Himes | Insider | Sell | 10,000 | $62.75 | $627,500.00 | 161,283 | |
| 3/6/2017 | Clay B Siegall | CEO | Sell | 14,465 | $68.04 | $984,198.60 | 646,858 | |
| 2/6/2017 | Clay B Siegall | Insider | Sell | 14,465 | $61.54 | $890,176.10 | 640,477 | |
| 1/6/2017 | Clay B. Siegall | Insider | Sell | 14,465 | $57.89 | $837,378.85 | | |
| 12/13/2016 | Darren S. Cline | EVP | Sell | 10,000 | $63.38 | $633,800.00 | | |
| 12/8/2016 | Eric Dobmeier | COO | Sell | 12,500 | $65.92 | $824,000.00 | | |
| 12/7/2016 | Vaughn B. Himes | Insider | Sell | 30,000 | $65.32 | $1,959,600.00 | | |
| 11/8/2016 | Felix Baker | Director | Buy | 382,500 | $59.36 | $22,705,200.00 | | |
| 11/7/2016 | Clay B. Siegall | CEO | Sell | 14,465 | $58.43 | $845,189.95 | | |
| 11/7/2016 | Marc E. Lippman | Director | Sell | 1,000 | $57.75 | $57,750.00 | | |
| 11/3/2016 | Felix Baker | Director | Buy | 1,030,629 | $56.13 | $57,849,205.77 | | |
| 11/1/2016 | Jonathan G. Drachman | CMO | Sell | 3,418 | $51.74 | $176,847.32 | | |
| 10/6/2016 | Clay B. Siegall | Insider | Sell | 14,465 | $54.41 | $787,040.65 | | |
| 9/22/2016 | Jonathan G Drachman | CMO | Sell | 2,249 | $56.75 | $127,630.75 | 115,504 | |
| 9/14/2016 | Eric Dobmeier | COO | Sell | 22,918 | $54.04 | $1,238,488.72 | | |
| 9/13/2016 | Felix Baker | Director | Buy | 447,311 | $50.71 | $22,683,140.81 | | |
| 9/8/2016 | Clay B. Siegall | Insider | Sell | 31,269 | $50.08 | $1,565,951.52 | | |
| 9/8/2016 | Felix Baker | Director | Buy | 414,016 | $48.43 | $20,050,794.88 | | |
| 8/23/2016 | Eric Dobmeier | COO | Sell | 12,589 | $48.00 | $604,272.00 | | |
| 8/22/2016 | Clay B. Siegall | Insider | Sell | 23,381 | $46.59 | $1,089,320.79 | | |
| 8/22/2016 | Eric Dobmeier | COO | Sell | 5,411 | $46.59 | $252,098.49 | | |
| 8/22/2016 | Vaughn B. Himes | EVP | Sell | 3,991 | $46.59 | $185,940.69 | | |
| 8/8/2016 | Clay B. Siegall | Insider | Sell | 11,660 | $47.19 | $550,235.40 | | |
| 7/27/2016 | Clay B. Siegall | Insider | Sell | 4,042 | $45.20 | $182,698.40 | | |
| 7/6/2016 | Clay B. Siegall | CEO | Sell | 7,618 | $40.56 | $308,986.08 | | |
| 6/6/2016 | Clay B Siegall | CEO | Sell | 22,083 | $43.59 | $962,597.97 | 566,538 | |
| 6/2/2016 | Darren S Cline | EVP | Sell | 3,366 | $42.07 | $141,607.62 | 42,747 | |
| 5/27/2016 | Clay B Siegall | CEO | Sell | 48,660 | $40.41 | $1,966,350.60 | 563,883 | |
| 5/24/2016 | Clay B Siegall | CEO | Sell | 8,400 | $40.09 | $336,756.00 | 562,815 | |
| 5/23/2016 | Clay B Siegall | CEO | Sell | 6,700 | $40.12 | $268,804.00 | 562,815 | |
| 5/17/2016 | Clay B Siegall | CEO | Sell | 7,618 | $35.16 | $267,848.88 | 563,733 | |
| 4/25/2016 | Clay B Siegall | CEO | Sell | 800 | $40.00 | $32,000.00 | 556,915 | |
| 4/5/2016 | Clay B Siegall | CEO | Sell | 7,618 | $36.12 | $275,162.16 | 563,733 | |
| 3/22/2016 | Clay B Siegall | CEO | Sell | 15,236 | $35.52 | $541,182.72 | 560,397 | |
| 3/21/2016 | Clay B Siegall | CEO | Sell | 4,282 | $35.01 | $149,912.82 | 560,397 | |
| 3/17/2016 | Felix Baker | Director | Buy | 124,065 | $31.85 | $3,951,470.25 | 38,783,387 | |
| 3/16/2016 | Felix Baker | Director | Buy | 1,349,237 | $32.10 | $43,310,507.70 | 107,511 | |
| 3/15/2016 | Felix Baker | Director | Buy | 661,093 | $32.08 | $21,207,863.44 | 38,671,506 | |
| 3/14/2016 | Felix Baker | Director | Buy | 118,941 | $33.77 | $4,016,637.57 | 38,671,506 | |
| 3/11/2016 | Felix Baker | Director | Buy | 694,666 | $32.46 | $22,548,858.36 | 37,454,776 | |
| 3/8/2016 | Felix Baker | Director | Buy | 502,523 | $22.66 | $11,387,171.18 | 107,511 | |
| 3/2/2016 | Felix Baker | Director | Buy | 675,922 | $31.77 | $21,474,041.94 | 107,511 | |
| 3/1/2016 | Felix Baker | Director | Buy | 24,200 | $31.24 | $756,008.00 | 107,511 | |
| 2/29/2016 | Felix Baker | Director | Buy | 251,722 | $30.39 | $7,649,831.58 | 107,511 | |
| 2/26/2016 | Felix Baker | Director | Buy | 314,508 | $29.55 | $9,293,711.40 | | |
| 2/22/2016 | Felix Baker | Director | Buy | 1,001,471 | $29.63 | $29,673,585.73 | | |
| 2/17/2016 | Felix Baker | Director | Buy | 1,269,147 | $30.43 | $38,620,143.21 | | |
| 2/12/2016 | John A. Orwin | Director | Buy | 2,000 | $28.33 | $56,660.00 | | |
| 12/15/2015 | Vaughn B. Himes | EVP | Sell | 40,500 | $39.94 | $1,617,570.00 | 76,212 | |
| 12/3/2015 | Clay B. Siegall | CEO | Sell | 3,720 | $39.99 | $148,762.80 | 556,115 | |
| 11/20/2015 | Felix Baker | Director | Buy | 329,358 | $43.94 | $14,471,990.52 | 107,504 | |
| 11/17/2015 | Clay B Siegall | CEO | Sell | 87,473 | $45.40 | $3,971,274.20 | 556,115 | |
| 11/11/2015 | Darren S Cline | SVP | Sell | 5,769 | $45.68 | $263,527.92 | 37,713 | |
| 11/10/2015 | Felix Baker | Director | Buy | 934,624 | $42.95 | $40,142,100.80 | 107,504 | |
| 11/9/2015 | Felix Baker | Director | Buy | 507,300 | $43.76 | $22,199,448.00 | 107,504 | |
| 11/6/2015 | Eric Dobmeier | COO | Sell | 17,452 | $42.50 | $741,710.00 | 80,888 | |
| 11/6/2015 | Felix Baker | Director | Buy | 417,924 | $41.94 | $17,527,732.56 | 107,504 | |
| 11/5/2015 | David W Gryska | Director | Sell | 10,000 | $43.57 | $435,700.00 | 23,950 | |
| 11/4/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $43.14 | $160,394.52 | 643,588 | |
| 10/5/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $41.30 | $153,553.40 | 611,323 | |
| 9/3/2015 | Clay B. Siegall | CEO | Sell | 3,718 | $40.12 | $149,166.16 | 611,323 | |
| 8/20/2015 | Clay B. Siegall | CEO | Sell | 31,754 | $42.02 | $1,334,303.08 | 611,323 | |
| 8/20/2015 | Darren S. Cline | SVP | Sell | 2,231 | $42.02 | $93,746.62 | 43,482 | |
| 8/20/2015 | Eric Dobmeier | COO | Sell | 8,548 | $42.02 | $359,186.96 | 98,340 | |
| 8/20/2015 | Jonathan G. Drachman | CMO | Sell | 4,462 | $42.02 | $187,493.24 | 82,724 | |
| 8/20/2015 | Todd E. Simpson | CFO | Sell | 5,825 | $42.02 | $244,766.50 | 179,874 | |
| 8/20/2015 | Vaughn B. Himes | EVP | Sell | 5,997 | $42.02 | $251,993.94 | 76,212 | |
| 7/6/2015 | Clay B Siegall | CEO | Sell | 3,718 | $46.94 | $174,522.92 | | |
| 6/3/2015 | Clay B Siegall | CEO | Sell | 3,718 | $45.72 | $169,986.96 | | |
| 5/21/2015 | Felix Baker | Director | Buy | 950,886 | $42.49 | $40,403,146.14 | | |
| 5/8/2015 | Eric Dobmeier | COO | Sell | 17,074 | $40.38 | $689,448.12 | | |
| 5/7/2015 | Felix Baker | Director | Buy | 1,032,664 | $35.56 | $36,721,531.84 | | |
| 3/10/2015 | Felix Baker | Director | Buy | 285,036 | $34.66 | $9,879,347.76 | | |
| 3/9/2015 | Felix Baker | Director | Buy | 275,717 | $34.66 | $9,556,351.22 | | |
| 3/4/2015 | Felix Baker | Director | Buy | 448,841 | $34.84 | $15,637,620.44 | | |
| 2/25/2015 | Felix Baker | Director | Buy | 281,115 | $33.92 | $9,535,420.80 | | |
| 1/6/2015 | Clay B Siegall | CEO | Sell | 16,804 | $31.80 | $534,367.20 | | |
| 12/16/2014 | Felix Baker | Director | Buy | 2,883,378 | $31.86 | $91,864,423.08 | | |
| 12/10/2014 | Felix Baker | Director | Buy | 1,247,896 | $33.82 | $42,203,842.72 | | |
| 12/9/2014 | Felix Baker | Director | Buy | 128,430 | $34.16 | $4,387,168.80 | | |
| 12/8/2014 | Felix Baker | Director | Buy | 465,316 | $32.93 | $15,322,855.88 | | |
| 11/12/2014 | Vaughn B Himes | EVP | Sell | 10,000 | $37.52 | $375,200.00 | | |
| 11/10/2014 | Felix Baker | Director | Buy | 1,653,925 | $34.56 | $57,159,648.00 | | |
| 9/4/2014 | Clay B Siegall | CEO | Sell | 5,600 | $42.54 | $238,224.00 | | |
| 8/12/2014 | Clay B Siegall | CEO | Sell | 11,200 | $40.38 | $452,256.00 | | |
| 8/11/2014 | Clay B Siegall | CEO | Sell | 2,700 | $40.05 | $108,135.00 | | |
| 6/13/2014 | Felix Baker | Director | Buy | 216,595 | $39.92 | $8,646,472.40 | | |
| 6/10/2014 | Clay B Siegall | CEO | Sell | 11,200 | $40.14 | $449,568.00 | | |
| 6/9/2014 | Felix Baker | Director | Buy | 546,252 | $38.16 | $20,844,976.32 | | |
| 6/4/2014 | Felix Baker | Director | Buy | 281,963 | $34.86 | $9,829,230.18 | | |
| 5/16/2014 | Felix Baker | Director | Buy | 189,611 | $34.07 | $6,460,046.77 | 76,997 | |
| 4/3/2014 | Clay Siegall | CEO | Sell | 5,600 | $43.34 | $242,704.00 | 955,696 | |
| 2/18/2014 | Clay Siegall | CEO | Sell | 100,000 | $51.97 | $5,197,000.00 | 955,696 | |
| 1/21/2014 | Eric Dobmeier | COO | Sell | 56,010 | $47.92 | $2,683,999.20 | 77,833 | |
| 1/16/2014 | Jonathan Drachman | CMO | Sell | 1,201 | $45.75 | $54,945.75 | 49,911 | |
| 12/16/2013 | Felix Baker | Director | Buy | 407,078 | $39.66 | $16,144,713.48 | 76,997 | |
| 12/5/2013 | Felix Baker | Director | Buy | 1,005,901 | $43.19 | $43,444,864.19 | 76,997 | |
| 10/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $43.87 | $87,740.00 | | |
| 9/10/2013 | Eric Dobmeier | COO | Sell | 42,000 | $46.40 | $1,948,800.00 | | |
| 9/5/2013 | Eric Dobmeier | COO | Sell | 75,000 | $42.64 | $3,198,000.00 | | |
| 9/3/2013 | Clay B Siegall | CEO | Sell | 102,000 | $43.90 | $4,477,800.00 | | |
| 9/3/2013 | David W Gryska | Director | Sell | 10,000 | $42.48 | $424,800.00 | | |
| 8/27/2013 | Todd Simpson | CFO | Sell | 37,763 | $41.45 | $1,565,276.35 | 155,395 | |
| 8/19/2013 | Clay Siegall | CEO | Sell | 7,653 | $40.91 | $313,084.23 | 1,124,558 | |
| 8/19/2013 | Eric Dobmeier | COO | Sell | 3,328 | $40.91 | $136,148.48 | 127,620 | |
| 8/19/2013 | Vaughn Himes | EVP | Sell | 1,736 | $40.91 | $71,019.76 | 46,307 | |
| 8/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $40.03 | $80,060.00 | | |
| 7/12/2013 | Todd E Simpson | CFO | Sell | 92,527 | $37.45 | $3,465,136.15 | | |
| 7/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $32.59 | $65,180.00 | | |
| 6/14/2013 | Srinivas Akkaraju | Director | Sell | 5,000 | $32.75 | $163,750.00 | | |
| 6/13/2013 | Vaughn B Himes | EVP | Sell | 10,000 | $32.11 | $321,100.00 | | |
| 6/3/2013 | Clay B Siegall | CEO | Sell | 2,000 | $33.88 | $67,760.00 | | |
| 5/10/2013 | Srinivas Akkaraju | Director | Sell | 17,500 | $37.17 | $650,475.00 | | |
| 3/6/2013 | Eric Dobmeier | COO | Sell | 100,000 | $29.68 | $2,968,000.00 | | |
| 2/25/2013 | David W Gryska | Director | Sell | 10,000 | $27.17 | $271,700.00 | | |
| 2/1/2013 | Clay B Siegall | CEO | Sell | 2,000 | $29.61 | $59,220.00 | | |
| 1/15/2013 | Thomas C Reynolds | Insider | Sell | 125,079 | $28.00 | $3,502,212.00 | | |
| 11/1/2012 | Clay B Siegall | CEO | Sell | 8,250 | $25.51 | $210,457.50 | | |
| 9/4/2012 | Clay B Siegall | CEO | Sell | 8,250 | $26.54 | $218,955.00 | | |
(Data available from 1/1/2013 forward)
Seattle Genetics (NASDAQ SGEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Anticipate Seattle Genetics (SGEN) Will Post Quarterly Sales of $139.99 Million
www.americanbankingnews.com - May 19 at 4:22 AM |
 | Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
finance.yahoo.com - May 17 at 5:34 PM |
| Seattle Genetics (SGEN) Receives Hold Rating from Cann
www.americanbankingnews.com - May 17 at 4:17 PM |
| Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
finance.yahoo.com - May 17 at 8:59 AM |
| Brokerages Anticipate Seattle Genetics (SGEN) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - May 17 at 5:15 AM |
| Seattle Genetics (SGEN) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM |
| Acorda Therapeutics (ACOR) versus Seattle Genetics (SGEN) Critical Comparison
www.americanbankingnews.com - May 15 at 10:46 AM |
 | Seattle Genetics Fairly Valued, Pending Data
seekingalpha.com - May 14 at 4:59 PM |
| Seattle Genetics (SGEN) CEO Sells $1,035,195.04 in Stock
www.americanbankingnews.com - May 11 at 10:38 PM |
| Darren S. Cline Sells 9,000 Shares of Seattle Genetics (SGEN) Stock
www.americanbankingnews.com - May 11 at 10:35 PM |
| Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant
seekingalpha.com - May 11 at 5:14 PM |
| Seattle Genetics (SGEN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 10 at 3:32 AM |
| Insider Buying: Seattle Genetics (SGEN) Director Buys 204,537 Shares of Stock
www.americanbankingnews.com - May 8 at 7:22 PM |
| Seattle Genetics (SGEN) Director Bros. Advisors Lp Baker Buys 460,651 Shares
www.americanbankingnews.com - May 8 at 7:22 PM |
| Seattle Genetics (SGEN) EVP Darren S. Cline Sells 4,000 Shares
www.americanbankingnews.com - May 7 at 10:26 PM |
| Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA
finance.yahoo.com - May 4 at 8:48 AM |
| The Bothell economy: City looks to Lake Union area as model to build up biotech hub
finance.yahoo.com - May 3 at 4:57 PM |
| Investors Buy High Volume of Seattle Genetics Call Options (SGEN)
www.americanbankingnews.com - May 3 at 8:21 AM |
| Seattle Genetics (SGEN) Director Purchases $15,763,257.12 in Stock
www.americanbankingnews.com - May 2 at 7:22 PM |
| BidaskClub Upgrades Seattle Genetics (SGEN) to "Sell"
www.americanbankingnews.com - May 2 at 1:04 PM |
| $125.16 Million in Sales Expected for Seattle Genetics (SGEN) This Quarter
www.americanbankingnews.com - May 1 at 2:22 AM |
| Seattle Genetics to Post FY2020 Earnings of $0.14 Per Share, William Blair Forecasts (SGEN)
www.americanbankingnews.com - April 30 at 4:40 AM |
| Seattle Genetics (SGEN) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - April 29 at 5:19 PM |
| Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top
finance.yahoo.com - April 27 at 4:55 PM |
| Edited Transcript of SGEN earnings conference call or presentation 26-Apr-18 8:30pm GMT
finance.yahoo.com - April 27 at 4:55 PM |
| Cantor Fitzgerald Reiterates "$50.00" Price Target for Seattle Genetics (SGEN)
www.americanbankingnews.com - April 27 at 10:30 AM |
| Seattle Genetics (SGEN) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 9:13 AM |
| Seattle Genetics: 1Q Earnings Snapshot
finance.yahoo.com - April 27 at 9:13 AM |
| Seattle Genetics searches for 10th building in effort to keep up with growth
finance.yahoo.com - April 27 at 9:13 AM |
| Seattle Genetics (SGEN) Posts Quarterly Earnings Results
www.americanbankingnews.com - April 26 at 11:52 PM |
| Seattle Genetics EPS of -$0.73
seekingalpha.com - April 26 at 4:55 PM |
| Seattle Genetics Q1 Adcetris sales up 36%
seekingalpha.com - April 26 at 4:55 PM |
| Seattle Genetics (SGEN) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 23 at 2:58 PM |
| Seattle Genetics (SGEN) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - April 20 at 8:00 PM |
| Piper Jaffray Reaffirms Neutral Rating for Seattle Genetics (SGEN)
www.americanbankingnews.com - April 20 at 4:16 PM |
| Seattle Genetics searches for its 10th building to keep up with growth
finance.yahoo.com - April 20 at 8:57 AM |
| Seattle Genetics (SGEN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:28 AM |
| ValuEngine Downgrades Seattle Genetics (SGEN) to Sell
www.americanbankingnews.com - April 15 at 10:59 AM |
| Seattle Genetics (SGEN) Rating Reiterated by Cowen
www.americanbankingnews.com - April 15 at 9:31 AM |
| Seattle Genetics (SGEN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 3:25 AM |
| Analysts Expect Seattle Genetics (SGEN) Will Announce Quarterly Sales of $119.58 Million
www.americanbankingnews.com - April 14 at 2:20 AM |
| Seattle Genetics (SGEN) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - April 12 at 5:22 PM |
| Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 12 at 9:30 AM |
| Clay B. Siegall Sells 18,832 Shares of Seattle Genetics (SGEN) Stock
www.americanbankingnews.com - April 11 at 10:37 PM |
| Nantkwest (NK) and Seattle Genetics (SGEN) Critical Comparison
www.americanbankingnews.com - April 9 at 7:14 AM |
| Seattle Genetics (SGEN) Coverage Initiated by Analysts at Oppenheimer
www.americanbankingnews.com - April 7 at 4:29 PM |
 | Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics
globenewswire.com - April 5 at 4:55 PM |
 | Seattle Genetics discloses pay for executives at the Puget Sound region's biggest biotech
www.bizjournals.com - April 5 at 4:55 PM |
| Seattle Genetics (SGEN) Downgraded by BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM |
| Unum Therapeutics closes IPO and private placement with Seattle Genetics
seekingalpha.com - April 4 at 8:52 AM |
Seattle Genetics (NASDAQ:SGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Seattle Genetics (NASDAQ:SGEN) Income Statement, Balance Sheet and Cash Flow Statement
Seattle Genetics (NASDAQ SGEN) Stock Chart for Sunday, May, 20, 2018
Loading chart…
